US OptionsDetailed Quotes

ALNY250516P360000

Watchlist

0.00
0.000.00%

15min DelayClose May 2 09:30 ET

0.00High0.00Low

Alnylam Pharmaceuticals Stock Discussion

Teddy123

Mar 31 10:04

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Sessi

$Alnylam Pharmaceuticals (ALNY.US)$
Groundbreaking HELIOS-B Trial: AMVUTTRA Proves Major Breakthrough for Heart Disease Patients

Teddy123

Mar 30 21:52

$Alnylam Pharmaceuticals (ALNY.US)$
Groundbreaking HELIOS-B Trial: AMVUTTRA Proves Major Breakthrough for Heart Disease Patients

Jerry Kronenberg

Mar 22 04:25

Columns Wall Street Today: Nasdaq Composite, S&P 500 and DJIA All Eke Out Gains

The Nasdaq Composite Index, S&P 500 and Dow Jones Industrial Average all rose slightly Friday during a session that failed to produce much volatility despite being 2025's first "triple-witching day."
After trading lower for much of the session, the $Nasdaq Composite Index (.IXIC.US)$ rebounded in Friday's final hour to end 93.43 points higher (0.5%) at 17,784.05.
The $S&P 500 Index (.SPX.US)$ likewise added 4.67 ticks (0.1%) to...

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?

Movers and Shakers

Mar 21 20:23

Columns Today's Pre-Market Movers and Top Ratings | FDX, NKE, QUBT and more

Morning Movers
Gapping Up
$Luminar Technologies (LAZR.US)$ jumped 7.2% after its fourth-quarter loss was less than anticipated and its $22.5 million in revenue exceeded the $17.8 million forecast. The company also reported an adjusted gross profit of $14 million, against Wall Street's expectation of a $12 million loss.
$Alnylam Pharmaceuticals (ALNY.US)$ increased 4.5% Premarket premarket after FDA expands approval for drug to trea...